- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00324870
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma
연구 개요
상세 설명
PRIMARY OBJECTIVES:
I. Determine the safety and tolerability of vorinostat (SAHA) in combination with bevacizumab in patients with unresectable or metastatic renal cell carcinoma. (Phase I) II. Determine the recommended dosing in patients treated with this regimen. (Phase I) III. Determine the proportion of patients who are progression-free at 6 months after receiving this regimen. (Phase II) IV. Determine the clinical response rate in patients treated with this regimen. (Phase II)
SECONDARY OBJECTIVES:
I. Determine the toxicity of this regimen in these patients. (Phase II) II. Determine time to progression and duration of progression-free and overall survival in patients treated with this regimen. (Phase II) III. Determine the pharmacodynamic effects in peripheral blood mononuclear cells and tumors before and after treatment with this regimen in these patients. (Phase II) IV. Determine the antiproliferative and apoptotic effects of this regimen in these patients. (Phase II) V. Determine the antiangiogenic effects of this regimen in these patients. (Phase II) VI. Determine the modulation of tumor metabolism and tumor blood flow in patients treated with this regimen. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of vorinostat (SAHA) followed by a phase II study.
PHASE I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.
PHASE II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I.
After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Salisbury, Maryland, 미국, 21801
- Peninsula Oncology and Hematology PA
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin Hospital and Clinics
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- No known CNS metastasis
- ECOG performance status 0-2
- Life expectancy > 6 months
- LVEF ≥ 45%
- Absolute neutrophil count ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST/ALT ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
- PT/INR ≤ 1.5
- Urine protein < 1+ by urinalysis OR < 1 g by 24-hour urine collection
- Not pregnant
- No nursing during and for 6 months after completion of study treatment
- Negative pregnancy test
- Fertile patients must use effective contraception for 2 weeks prior, during, and for 6 months after completion of study treatment
- No other currently active malignancy defined as > 30% risk of relapse upon completion of anticancer therapy, except nonmelanoma skin cancer
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat (SAHA)
- No hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No evidence of bleeding diathesis or coagulopathy
- No active bleeding or pathological conditions that carry high risk of bleeding (i.e., tumor involving major vessels or known varices)
- No ongoing, active infection
- No New York Heart Association class II-IV congestive heart failure
- No angina pectoris requiring nitrate therapy
- No cardiac arrhythmia
- No myocardial infarction within the past 6 months
- No history of cerebrovascular accident within the past 6 months
- No uncontrolled hypertension (defined as systolic blood pressure (BP) > 160 mm Hg and/or diastolic BP > 90 mm Hg on medication)
- No history of peripheral vascular disease
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled illness
- No serious nonhealing wound, ulcer, or bone fracture
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- No significant traumatic injury in the past 28 days
- At least 4 weeks since prior major surgery or open biopsy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- More than 4 weeks since prior radiotherapy
- At least 2 weeks since prior tyrosine kinase inhibitor
- Prior palliative radiotherapy to metastatic lesions allowed provided ≥ 1 measurable and/or evaluable lesion has not been irradiated
- No more than 2 prior systemic treatments for metastatic disease, including immunotherapy, receptor tyrosine kinase inhibitor therapy, chemotherapy, or investigational therapy
- No prior therapy with bevacizumab, vascular endothelial growth factor-trap, or histone deacetylase inhibitors, including valproic acid
- No core biopsy within 1 week prior to day 1 of study treatment
- No planned major surgery during study treatment
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents
- Concurrent stable-dose prophylactic anticoagulation (i.e., warfarin or low molecular weight heparin) allowed provided requirements for INR are met
- Histologically confirmed renal cell carcinoma, clear cell component, unresectable or metastatic disease (patients with a primary tumor in place who are eligible for surgery are strongly encouraged to undergo a nephrectomy prior to study entry to increase potential survival)
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm with spiral CT scan
The following histologies are not allowed:
- Papillary, sarcomatoid carcinoma
- Chromophobe carcinoma
- Oncocytoma
- Collecting duct tumor
- Transitional cell carcinoma
- WBC ≥ 3,000/mm^3
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Arm I
Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD. Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I. |
구두로 주어진
다른 이름들:
주어진 IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Progression-free Survival Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) (Phase II)
기간: At 6 months
|
Estimated by Kaplan-Meier method
|
At 6 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Maximum Tolerated Dose
기간: 18 months from first patient dosing
|
Determine the maximum tolerated dose of SAHA
|
18 months from first patient dosing
|
Clinical Response Rate of SAHA and Bevacizumab
기간: 7 years
|
To determine the clinical response rate of SAHA and Bevacizumab in patients with metastatic renal cell carcinoma.
|
7 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Michael Carducci, Johns Hopkins University/Sidney Kimmel Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NCI-2009-00093 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- P30CA006973 (미국 NIH 보조금/계약)
- U01CA070095 (미국 NIH 보조금/계약)
- U01CA062491 (미국 NIH 보조금/계약)
- 6884 (기타 식별자: CTEP)
- NA 00001107
- NCI-6884
- JHOC-J0570
- CDR0000467800
- JHOC-00001107
- J0570
- IRB #NA 00001107, SKCCC J0570 (기타 식별자: Johns Hopkins University/Sidney Kimmel Cancer Center)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
투명 세포 신장 세포 암종에 대한 임상 시험
-
Sandy SrinivasGlaxoSmithKline완전한방광암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전) | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성) | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능미국
-
Stanford UniversityNational Institutes of Health (NIH)빼는방광암 | 피부암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전)미국
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.모병미만성 거대 B세포 림프종 | 재발성 미만성 대형 B세포 림프종 | 난치성 미만성 대형 B세포 림프종 | 원발성 종격동(흉선) 대형 B세포 림프종 | 등급 3b 여포성 림프종 | 변형된 여포 림프를 Diff 대형 B-세포 림프종으로 | 변형된 마그 존 림프를 Diff Large B-Cell Lymphoma로미국
-
University of Alabama at Birmingham종료됨역형성 대세포 림프종 | 혈관면역모세포성 T세포 림프종 | 말초 T 세포 림프종 | 성인 T 세포 백혈병 | 성인 T 세포 림프종 | 상세불명의 말초 T 세포 림프종 | T/Null Cell 전신형 | 림프절/내장 질환을 동반한 피부 T세포 림프종미국
보리노스타트에 대한 임상 시험
-
Johns Hopkins All Children's Hospital종료됨
-
Merck Sharp & Dohme LLC더 이상 사용할 수 없음림프종, T 세포, 피부
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, Bonn; University of Göttingen종료됨
-
Merck Sharp & Dohme LLC완전한균상 식육종 | 시자리 증후군 | 피부 T 세포 림프종
-
Merck Sharp & Dohme LLC종료됨
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLC종료됨
-
Samsung Medical CenterSeok Jin Kim종료됨